Sanofi Terminates Phase 1 Trial and Development of STAT6 Degrader SAR448272

Nurix Therapeutics announced that its collaboration partner, Sanofi, has discontinued the Phase 1 clinical trial and terminated the development program for SAR448272, an oral STAT6 degrader. As a result, Nurix will not receive any future milestone payments or royalties associated with this specific drug candidate.

Key Details

• Program Discontinued: Sanofi has decided to stop the first-in-human Phase 1 trial for the oral STAT6 degrader SAR448272 and terminate the program.
• Financial Impact: Nurix no longer expects to receive any future development, regulatory, or commercial milestone payments and royalties that were previously eligible under the collaboration for the SAR448272 program.
• Ongoing Collaboration: The termination is specific to the SAR448272 program. Nurix remains eligible for potential milestones and royalties from other licensed programs under its collaboration with Sanofi.